Physician profile
Babak Eliassi Rad
NPI 1013903822
$6,382.82
in general payments reported to CMS, 2019-2025
10 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.74 · 2020: $293 · 2021: $353 · 2022: $1,045 · 2023: $862 · 2024: $1,981 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,604 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,603.90 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,133.68 | 2020-2025 | Idose, Idosetr, Radius |
| Abbvie INC. | $1,453.17 | 2022-2025 | |
| Alcon Vision LLC | $650.15 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Beaver-Visitec International, INC. | $650.00 | 2022 | |
| New World Medical,INC. | $592.51 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Allergan, INC. | $501.93 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $138.29 | 2022 | |
| Aerie Pharmaceuticals, INC. | $125.00 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $116.88 | 2024 | Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $21.21 | 2025 | Vyzulta, Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Eliassi Rad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.